Navigation Links
454 sequencing uncovers significant genetic variation
Date:9/27/2007

BRANFORD, Conn., Sept. 27, 2007 454 Life Sciences, a Roche company, in collaboration with Yale University researchers today announced that they have developed a method, using the companys Genome Sequencer system, to identify significant human genetic variability with an unprecedented level of detail. The new method enables researchers to analyze genome-wide structural variations (SV), the gross changes to the genetic code much faster and economically than existing techniques. The study, entitled "Paired-End Mapping Reveals Extensive Genomic Structural Variation in Humans," appears online (ahead of print) today in the journal Science.

Previous studies of human genomic variation tended to look at changes called single nucleotide polymorphism, variations that involve just one nucleotide, commonly referred to as SNP. However, the study published today suggests that structural variation is responsible for a larger number of differences between the genomes of two individuals than SNPs. Furthermore, structural variation may have notable physical effects on an individual. The role that SV plays in human variability has not been well understood because of cost-prohibitive and imprecise technology used in previous research. The novel approach described today in Science, called Paired End Mapping (PEM), used 454 Sequencing to comprehensively study SV at an unmatched level of precision, detecting most of the structural variation in the human genome.

454 Sequencing enabled us to efficiently identify over 1000 structural variations in two individuals. Our study demonstrates that a large number of SVs are present in the human population and that SV plays a greater role in genetic diversity than SNP, explained Michael Snyder, PhD., senior author and Lewis B. Cullman Professor of Molecular, Cellular and Developmental Biology and Professor of Molecular Biophysics and Biochemistry; Director of the Yale Center for Genomics and Proteomics. The widespread occurrence of structural variation and the observation that many genes are affected, suggests that SV is likely to be a major form of human variation. It will be essential to incorporate SV detection in human genome sequencing projects.

Although SVs were found throughout the genome, researchers found that many SVs are concentrated in specific regions or hot spots. Several of these hot-spots are regions of the genome known to correlate to some genetic diseases such as Velocardiofacial Syndrome, and Williams-Beuren Syndrome. Furthermore, structural variation may affect gene function by altering the frequency of a given gene, changing its structure, or alter how the gene is regulated.

454 Sequencing can generate hundreds of thousands of long read pairs that are unique within the human genome to quickly and accurately determine genomic variations, explained Michael Egholm, Ph.D., co-author of the study and vice president of research and development at 454 Life Sciences. This highly accurate study of human genomic structural variation along with the recently sequenced genome of Jim Watson confirms that 454 Sequencing is the first affordable technology to offer a comprehensive view of the human genome.


'/>"/>

Contact: Benjamin Carmichael
benjamin.carmichael@russopartnersllc.com
212-845-4242
Noonan/Russo Communications
Source:Eurekalert

Related biology technology :

1. Purified Single-Stranded M13 DNA for Automated Sequencing
2. Automated Fluorescent-Tag Cycle Sequencing
3. Eppendorf Mastercycler ABI Big Dye Sequencing Protocol
4. END SEQUENCING
5. FULL LENGTH INSERT SEQUENCING
6. WHOLE GENOME SEQUENCING
7. SAGE & LONGSAGE SEQUENCING
8. SINGLE PASS SEQUENCING
9. QuickLane 24 - 48 Hour Sequencing
10. cDNA Sequencing & Finishing
11. Comparison of PCR Kleen Spin Columns to Traditional Methods for Purification of PCR Products Prior to Sequencing, Rev A
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... ... 23, 2017 , ... AxioMed will be presenting its viscoelastic ... in Montego Bay, Jamaica from January 26-28th. “We’re excited to be presenting the ... experience the simplicity of the surgical technique,” said Jake Lubinski, President of AxioMed. ...
(Date:1/21/2017)... , ... January 21, 2017 , ... ... endeavors to bring to market a pioneering medical device for the treatment of ... an engagement contract with Emergo, a global regulatory consultancy that helps companies like ...
(Date:1/21/2017)... , Jan. 21, 2017   Boston Biomedical ... compounds designed to target cancer stemness pathways, today presented ... compound, napabucasin, at the 2017 American Society of Clinical ... Francisco . In a Phase ... agent designed to inhibit cancer stemness pathways by targeting ...
(Date:1/20/2017)... -- http://www.Financialbuzz.com - According to ... of death worldwide. There were 8.2 million cancer related ... deaths increased gradually over time, the death rates have ... cancers continues to drive demand of biological therapies for ... Insights, Inc. cancer biological therapy market size was USD 61.3 ...
Breaking Biology Technology:
(Date:1/12/2017)...  Trovagene, Inc. (NASDAQ: TROV ), a ... that it has signed agreements with seven strategic partners ... Middle East for commercialization of the ... wave of international distribution agreements for Trovagene,s CLIA based ... The initial partners will introduce Trovagene,s liquid biopsy ...
(Date:1/12/2017)... PUNE, India , January 12, 2017 A new report ... 2022," projects that the global biometric technology market is expected to generate revenue of ... Continue Reading ... Allied ...      (Logo: http://photos.prnewswire.com/prnh/20140911/647229) ...
(Date:1/11/2017)... , Jan. 11, 2017  Michael Johnson, co-founder of Visikol ... Capital Group, Inc., has been named to the elite "Forbes 30 ...  was one of 600 people in 20 fields nationwide to be ... of the 15,000 applicants were selected. ... He is currently a PhD candidate at Rutgers ...
Breaking Biology News(10 mins):